Harmony Highlights 2025 Key Catalysts as Wakix Revenue Grows 23%
Summary: Harmony Biosciences reported preliminary revenue for 2024, with Wakix generating $714 million, a 23% increase from 2023. The company outlined its 2025 key catalysts, including an FDA decision on pitolisant for idiopathic hypersomnia, the initiation of a pivotal trial for Pitolisant-HD in narcolepsy, and preclinical data for BP1.15205, an OX2R agonist. These milestones reflect…